Homozygous MTAP deletion in primary human glioblastoma is not associated with elevation of methylthioadenosine
暂无分享,去创建一个
R. Verhaak | J. Huse | J. D. de Groot | R. Kalluri | F. Muller | J. Asara | Dimitra K. Georgiou | A. deCarvalho | Lin Wang | Yu-Hsi Lin | N. Satani | Victoria C. Yan | Sunada Khadka | Kenisha Arthur | J. Ackroyd | Elliot S Ballato | Yasaman Barekatain | Eliot I Behr | Ko-Chien Chen | Theresa Tran | Anton H. Poral
[1] A. Falini,et al. Tumours , 2008, Neurological Sciences.
[2] Gary D Bader,et al. PRMT5 inhibition disrupts splicing and stemness in glioblastoma , 2021, Nature Communications.
[3] W. Liu,et al. MAT2A inhibition blocks the growth of MTAP-deleted cancer cells by reducing PRMT5-dependent mRNA splicing and inducing DNA damage. , 2021, Cancer cell.
[4] R. DePinho,et al. An Enolase Inhibitor for the Targeted Treatment of ENO1-Deleted Cancers , 2020, Nature Metabolism.
[5] Minoru Kanehisa,et al. KEGG: integrating viruses and cellular organisms , 2020, Nucleic Acids Res..
[6] Wenzhi Sun,et al. Using arterial–venous analysis to characterize cancer metabolic consumption in patients , 2020, Nature Communications.
[7] Nicholas D. Adams,et al. Anti-tumor Activity of the Type I PRMT Inhibitor, GSK3368715, Synergizes with PRMT5 Inhibition through MTAP Loss. , 2019, Cancer cell.
[8] J. Locasale,et al. Nutrient availability shapes methionine metabolism in p16/MTAP-deleted cells , 2019, Science Advances.
[9] T. Ackermann,et al. Cell Culture Medium Formulation and Its Implications in Cancer Metabolism. , 2019, Trends in cancer.
[10] G. G. Galli,et al. The landscape of cancer cell line metabolism , 2019, Nature Medicine.
[11] M. Zampieri,et al. Metabolic profiling of cancer cells reveals genome-wide crosstalk between transcriptional regulators and metabolism , 2019, Nature Communications.
[12] G. Finocchiaro,et al. The landscape of the mesenchymal signature in brain tumours , 2019, Brain : a journal of neurology.
[13] Xiaobing Shi,et al. PRMT1 loss sensitizes cells to PRMT5 inhibition , 2019, Nucleic acids research.
[14] Sung-Liang Yu,et al. Targeting the insulin-like growth factor-1 receptor in MTAP-deficient renal cell carcinoma , 2019, Signal Transduction and Targeted Therapy.
[15] Gabriela Kalna,et al. Improving the metabolic fidelity of cancer models with a physiological cell culture medium , 2019, Science Advances.
[16] I. Nakano,et al. Integrative cross-platform analyses identify enhanced heterotrophy as a metabolic hallmark in glioblastoma , 2018, Neuro-oncology.
[17] T. Köcher,et al. RIOK1 kinase activity is required for cell survival irrespective of MTAP status , 2018, Oncotarget.
[18] A. Riccio,et al. H3.3K27M Cooperates with Trp53 Loss and PDGFRA Gain in Mouse Embryonic Neural Progenitor Cells to Induce Invasive High-Grade Gliomas. , 2017, Cancer cell.
[19] Steven D Chang,et al. Single-Cell RNAseq analysis of infiltrating neoplastic cells at the migrating front of human glioblastoma , 2017, bioRxiv.
[20] Y. Lotan,et al. Metabolomics analysis reveals distinct profiles of nonmuscle‐invasive and muscle‐invasive bladder cancer , 2017, Cancer medicine.
[21] Edward F. Chang,et al. Tumor Evolution of Glioma-Intrinsic Gene Expression Subtypes Associates with Immunological Changes in the Microenvironment. , 2017, Cancer cell.
[22] Steven J. M. Jones,et al. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma , 2017, Cell.
[23] R. DePinho,et al. SF2312 is a natural phosphonate inhibitor of Enolase , 2016, Nature chemical biology.
[24] A. Kernytsky,et al. MTAP Deletions in Cancer Create Vulnerability to Targeting of the MAT2A/PRMT5/RIOK1 Axis. , 2016, Cell reports.
[25] T. Golub,et al. MTAP deletion confers enhanced dependency on the PRMT5 arginine methyltransferase in cancer cells , 2016, Science.
[26] Konstantinos J. Mavrakis,et al. Disordered methionine metabolism in MTAP/CDKN2A-deleted cancers leads to dependence on PRMT5 , 2016, Science.
[27] Chris Sander,et al. An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. , 2016, Cancer cell.
[28] R. DePinho,et al. Collateral Lethality: A new therapeutic strategy in oncology. , 2015, Trends in cancer.
[29] Steven J. M. Jones,et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.
[30] Robert A Copeland,et al. A selective inhibitor of PRMT5 with in vivo and in vitro potency in MCL models. , 2015, Nature chemical biology.
[31] Jill S Barnholtz-Sloan,et al. Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution , 2015, Genome research.
[32] Thomas D. Wu,et al. A comprehensive transcriptional portrait of human cancer cell lines , 2014, Nature Biotechnology.
[33] Annette M Molinaro,et al. Characterization of metabolites in infiltrating gliomas using ex vivo 1H high-resolution magic angle spinning spectroscopy , 2014, NMR in biomedicine.
[34] Jing Fan,et al. Quantitation of cellular metabolic fluxes of methionine. , 2014, Analytical chemistry.
[35] D. Haussler,et al. The Somatic Genomic Landscape of Glioblastoma , 2013, Cell.
[36] Wolfram Gronwald,et al. Distinct metabolic differences between various human cancer and primary cells , 2013, Electrophoresis.
[37] Benjamin E. Gross,et al. Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal , 2013, Science Signaling.
[38] K. Kohn,et al. 268 CellMiner: a Web-Based Suite of Genomic and Pharmacologic Tools to Explore Transcript and Drug Patterns in the NCI-60 Cell Line Set , 2012 .
[39] L. Chin,et al. Passenger Deletions Generate Therapeutic Vulnerabilities in Cancer , 2012, Nature.
[40] K. Kohn,et al. CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. , 2012, Cancer research.
[41] Mauro Delorenzi,et al. DNA fingerprinting of glioma cell lines and considerations on similarity measurements. , 2012, Neuro-oncology.
[42] Benjamin E. Gross,et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.
[43] J. Asara,et al. A positive/negative ion–switching, targeted mass spectrometry–based metabolomics platform for bodily fluids, cells, and fresh and fixed tissue , 2012, Nature Protocols.
[44] L. Cantley,et al. Metabolomics of Human Cerebrospinal Fluid Identifies Signatures of Malignant Glioma* , 2012, Molecular & Cellular Proteomics.
[45] Yu-Jie Hu,et al. Versatility of PRMT5-induced methylation in growth control and development. , 2011, Trends in biochemical sciences.
[46] Helmut Kettenmann,et al. The brain tumor microenvironment , 2011, Glia.
[47] Gang Su,et al. Integrated metabolome and transcriptome analysis of the NCI60 dataset , 2011, BMC Bioinformatics.
[48] Helga Thorvaldsdóttir,et al. Integrative Genomics Viewer , 2011, Nature Biotechnology.
[49] Darell D. Bigner,et al. Integrated genomic analyses identify ERRFI1 and TACC3 as glioblastoma-targeted genes , 2010, Oncotarget.
[50] Peter J. Oefner,et al. Quantification of intermediates of the methionine and polyamine metabolism by liquid chromatography-tandem mass spectrometry in cultured tumor cells and liver biopsies. , 2010, Journal of chromatography. A.
[51] Derek Y. Chiang,et al. The landscape of somatic copy-number alteration across human cancers , 2010, Nature.
[52] P. Oefner,et al. Direct and tumor microenvironment mediated influences of 5′‐deoxy‐5′‐(methylthio)adenosine on tumor progression of malignant melanoma , 2009, Journal of cellular biochemistry.
[53] D. Busam,et al. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2008, Science.
[54] P. Kehrli,et al. Toward improved grading of malignancy in oligodendrogliomas using metabolomics , 2008, Magnetic resonance in medicine.
[55] Masakazu Toi,et al. Angiogenic inhibitors: a new therapeutic strategy in oncology , 2005, Nature Clinical Practice Oncology.
[56] R. Hruban,et al. Concordant loss of MTAP and p16/CDKN2A expression in pancreatic intraepithelial neoplasia: evidence of homozygous deletion in a noninvasive precursor lesion , 2005, Modern Pathology.
[57] M. Mann,et al. A Novel WD Repeat Protein Component of the Methylosome Binds Sm Proteins* , 2002, The Journal of Biological Chemistry.
[58] Juri Rappsilber,et al. The Methylosome, a 20S Complex Containing JBP1 and pICln, Produces Dimethylarginine-Modified Sm Proteins , 2001, Molecular and Cellular Biology.
[59] G. Fuller,et al. An implantable guide-screw system for brain tumor studies in small animals. , 2000, Journal of neurosurgery.
[60] Richard A. Ashmun,et al. Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19 ARF , 1997, Cell.
[61] M. Diccianni,et al. Frequent deletion in the methylthioadenosine phosphorylase gene in T-cell acute lymphoblastic leukemia: strategies for enzyme-targeted therapy. , 1996, Blood.
[62] G. Hannon,et al. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.
[63] C. Betsholtz,et al. Evidence for progressional changes in the human malignant glioma line U-343 MGa: analysis of karyotype and expression of genes encoding the subunit chains of platelet-derived growth factor. , 1987, Cancer research.
[64] D. Carson,et al. Modulation of adenine nucleoside excretion and incorporation in adenosine deaminase deficient human lymphoma cells. , 1984, Biochemical and biophysical research communications.
[65] M. Riscoe,et al. 5-Methylthioribose. Its effects and function in mammalian cells. , 1984, The Journal of biological chemistry.
[66] N. Kamatani,et al. Abnormal regulation of methylthioadenosine and polyamine metabolism in methylthioadenosine phosphorylase-deficient human leukemic cell lines. , 1980, Cancer research.
[67] S. Eschrich,et al. Molecular and Cellular Pathobiology The Metabolomic Signature of Malignant Glioma Re fl ects Accelerated Anabolic Metabolism , 2012 .
[68] A. Børresen-Dale,et al. Analyzing cancer samples with SNP arrays. , 2012, Methods in molecular biology.
[69] P. Oefner,et al. Gastrointestinal , Hepatobiliary , and Pancreatic Pathology Down-Regulation of Methylthioadenosine Phosphorylase ( MTAP ) Induces Progression of Hepatocellular Carcinoma via Accumulation of 5 =-Deoxy-5 =-Methylthioadenosine ( MTA ) , 2011 .
[70] T. Savarese,et al. Codeletion of the genes for p16INK4, methylthioadenosine phosphorylase, interferon-alpha1, interferon-beta1, and other 9p21 markers in human malignant cell lines. , 1996, Cancer genetics and cytogenetics.